Regeneus (ASX:RGS) is set to receive a milestone payment of US$1 million for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis.
Progenza is Regeneus’s flagship asset, and is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.
South Canterbury farmer and science leader William Rolleston steps down from his role as Federated Farmers national president on Thursday.
Shortly after either vice-president Anders Crofoot or board member Katie Milne will be elected in his place.
Amazon has acquired Whole Foods, a move that marks the ecommerce giant’s official entry into the world of brick-and-mortar stores as well as groceries.
It’s Amazon’s biggest acquisition ever—and it’s not even close. The company is paying $13.7 billion in cash for the grocery chain, which now operates some 465 stores across the U.S.
Local bankers and lawyers expect a strong final half for mergers and acquisitions, after a jump in activity and resurgence in private equity-led deals so far this year.
Those canvassed by The Australian Financial Review said the pipeline of M&A deals was healthy, and buoyed by large pools of global capital that had to be deployed and favourable funding markets. They expect a strong rather than stellar finish to 2017.
It’s been a big week for Australia’s growing medical cannabis industry, with ethics approval granted for two human trials as well as the formation of a new joint venture.
Life science company Medlab Clinical Limited has received Human Research Ethics Committee (HREC) approvals to begin human trials of two different cannabis-based medicines. Developed at Medlab’s Sydney laboratory, the patent-pending medicines have two different applications and will be clinically tested at different locations.
BIOTECHNOLOGY can be risky, but a new study shows that almost 60 per cent of life-science companies have grown in stockmarket size over the past three years.
At least 25 out of 101 surveyed companies had doubled their market capitalisation, the study by sector analysts Bioshares found. Fifteen of the 101 companies listed since June 2015 had at least tripled.
For decades now, we’ve been promised cheap biofuels from algae. But there’s no free lunch. Growing these mini oil factories in vast ponds requires fertiliser and mechanical aeration; and then the oil has to be extracted. It all costs energy and money so the yields need to be high to make it worthwhile.
One promising industrial species is Nannocholoropsis gaditana, which can produce a lipid – the oil and fat energy store – content up to about 60% of the algae’s ash-free dry weight. But Eric Moellering and colleagues at the company Synthetic Genomics Inc in California, wanted to do better.
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the achievement of the second of two preclinical milestones in connection with its collaboration with LEO Pharma.”Our collaboration with LEO Pharma continues to be highly productive with the announcement of this most recent preclinical milestone. This achievement is the second of two success-based preclinical milestones with the first having been received last year.
SAN DIEGO, USA: International bio investors have been invited to Brisbane after Premier Annastacia Palaszczuk announced the Queensland capital will play host next year to a gathering of the leading players in one of Australia’s most exciting and promising high-tech industries.
Speaking at the BIO International Convention in San Diego in the United States, Ms Palaszczuk said almost 1000 business leaders, investors and scientists from Australia and overseas would attend the AusBiotech 2018 national conference from 31 October to 2 November at the Brisbane Convention and Exhibition Centre next year.
Making biofuel from algae has just got a little bit easier, as a newly engineered strain produces twice as much oil as its wild parent, according to Californian researchers.
Previous attempts to get this type of algae to make more oil crippled its growth, which isn’t an issue with this new strain. Without the growth restrictions, we are now one step closer to producing biodiesel on a large scale, say the researchers.